Trinity Biotech plc (NASDAQ:TRIB) stock surged 73% after the company announced it received regulatory approval from the New York State Department of Health for its PreClara™ Ratio biomarker test for preeclampsia risk assessment.
The FDA-cleared test will be provided through Trinity’s New York reference laboratory, with service rollout planned for the third quarter of 2025. The approval represents a significant milestone in the company’s maternal health strategy and strengthens its position in the U.S. diagnostics market.
The PreClara™ test provides clinicians with information to support decision-making for patients hospitalized with hypertensive disorders of pregnancy, which affect approximately 500,000 women annually in the United States. These disorders are a leading cause of maternal and neonatal complications.
According to recent U.S.-based studies published in March 2025, incorporating the test into standard care could potentially generate neonatal cost savings exceeding $10 million per 1,000 patients, primarily through reduced preterm deliveries and NICU admissions.
The regulatory approval also establishes groundwork for the anticipated commercial introduction of PrePsia™, Trinity Biotech’s proprietary preeclampsia risk assessment technology designed for use in early pregnancy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.